Dyne Therapeutics, Inc.

NASDAQ:DYN

Biotechnology

Healthcare
$16.02 +1.97%

+$0.38 today

Market cap
$3.00B
Beta
1.08
P/E (TTM)
-7.2
EPS (TTM)
-$2.74
52W Low $8.06High $25.00

Volume 2.06M

Average 1.71M

DYN Operating Margin

Operating income as a percentage of revenue, showing the profitability of core operations.

Dyne Therapeutics, Inc.NASDAQ: DYN

Operating Margin · Q2 FY2026 · quarter ended Jun 2026

Operating margin not reported for Q2 FY2026

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
—— QoQ
Last fiscal yearDec 2025
—— YoY
LTMJun 2026
—— YoY
Operating Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

Operating Margin history

Percent of revenue · from the income statement

No Operating Margin data reported for this period type.

Operating Margin vs competitors

How DYN compares with its peers on the latest reported figures

DYN Competitors Peer median
Operating Margin for DYN and competitors
Company Period LTM level YoY 3-year change
PTCTPTC Therapeutics, Inc.LTM Jun 202611.5% -29.2 pp+113.5 pp
SRPTSarepta Therapeutics, Inc.LTM Mar 2026-1.9% +3.4 pp+27.5 pp
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026-58.9% -30.2 pp+29.4 pp
WVEWave Life Sciences Ltd.LTM Mar 2026-274.2% -154.4 pp+3955.2 pp
STOKStoke Therapeutics, Inc.LTM Mar 2026-577.5% -597.5 pp+830.1 pp
TRDAEntrada Therapeutics, Inc.LTM Mar 2026-3109.3% -3111.7 pp—
DYNDyne Therapeutics, Inc.FY2025— ——
SLDBSolid Biosciences Inc.FY2025— ——
CAPRCapricor Therapeutics, Inc.FY2025— ——
LRMRLarimar Therapeutics, Inc.FY2025— ——
PEPGPepGen Inc.FY2025— ——
Peer median (excluding DYN) -166.6%-92.3 pp+113.5 pp

Competitors are the stored peer set for DYN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue002.46M2.24M2.05M
Gross Profit00(2.46M)(2.24M)(2.05M)
Gross Margin—————
Research & Development121.31M142.76M210.76M281.41M398.33M
Selling, General & Admin28.72M28.2M31.4M62.48M69.85M
Operating Expenses150.03M170.96M239.7M341.64M466.14M
Depreciation & Amortization1.09M1.68M1.67M1.67M2.05M
EBITDA(148.2M)(163.5M)(234.26M)(315.75M)(437.97M)
EBITDA Margin—————
Operating Income(150.03M)(170.96M)(242.16M)(343.89M)(468.18M)
Operating Margin—————
Interest Income742K2.92M7.64M26.92M29.86M
Interest Expense02.92M006.19M
Other Income / Expenses734K2.86M6.23M26.47M21.97M
Income Before Tax(149.29M)(168.1M)(235.94M)(317.42M)(446.21M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(149.29M)(168.1M)(235.94M)(317.42M)(446.21M)
Net Margin—————
EPS (Basic)(2.93)(3.23)(3.95)(3.37)(3.47)
EPS (Diluted)(2.93)(3.23)(3.95)(3.37)(3.47)
Weighted Avg Shares50.9M51.98M59.68M94.14M128.44M
Weighted Avg Shares (Diluted)50.9M51.98M59.68M94.14M128.44M

Dyne Therapeutics, Inc.

NASDAQ:DYN

Intrinsic Alpha fair value

Locked

Current Price

$16.02

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.